Clinicopathological and molecular characteristics and treatment outcomes of SMARCA4-deficient thoracic tumors: a comprehensive analysis
This study provides a comprehensive analysis of SDTT to date, based on a relatively large sample size. STK11/KRAS co-mutations are associated with poorer prognosis. SMARCA4-dNSCLC can be distinguished from SMARCA4-dUT by epithelial markers and stem cell markers. Immune-based therapy is the optimal option in the current treatment strategy.
Authors
- Xun Yuan (ORCID: https://orcid.org/0000-0003-4076-0517)
- Qian Chu (ORCID: https://orcid.org/0000-0001-6550-6975)
- Fangfang Liu (ORCID: https://orcid.org/0000-0001-9792-1911)
- Ying Liu (ORCID: https://orcid.org/0009-0000-7194-2378)
- Chengyan Wang (ORCID: https://orcid.org/0000-0002-4832-4480)
- Yuheng Yan
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1093/oncolo/oyaf266
- Citations
- 4
- Primary Topic
- Chromatin Remodeling and Cancer
- Type
- article
- Field-Weighted Citation Impact
- 3.22